Aiming at the sweet side of cancer: Aberrant glycosylation as possible target for personalized-medicine

Vered Padler-Karavani

doi:10.1016/j.canlet.2013.10.005

Aiming at the sweet side of cancer: Aberrant glycosylation as possible target for personalized-medicine

Vered Padler-Karavani

Department of Cell Research and Immunology

Tel Aviv University

Research output: Contribution to journal › Review article › peer-review

Abstract

One of the frontiers in cancer personalized-medicine aims at glycosylation. Cells are covered with a dense sugar coat of glycolipids, glycoproteins and free glycans. In cancer, the characteristic cell surface glycosylation is frequently transformed due to altered expression of glycan-modifying enzymes. This often leads to aberrant expression of sialic acids (Sia) that cap glycan-chains. Additionally, dietary intake of the non-human Sia N-glycolylneuraminic acid (Neu5Gc) leads to natural metabolic-glycoengineering of human carcinomas that accumulate and express Neu5Gc. This Sia provokes a polyclonal anti-Neu5Gc xeno-autoantibodies response that can exacerbate cancer. This review highlights cancer-associated changes in Sia expression and their potential for personalized-theranostics.

Original language	English
Pages (from-to)	102-112
Number of pages	11
Journal	Cancer Letters
Volume	352
Issue number	1
DOIs	https://doi.org/10.1016/j.canlet.2013.10.005
State	Published - 28 Sep 2014

Keywords

Antibodies
Cancer
Neu5Gc
Personalized-medicine
Sialic acids

All Science Journal Classification (ASJC) codes

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.canlet.2013.10.005

Cite this

@article{263a389d168948ba8f32464a95ddecad,

title = "Aiming at the sweet side of cancer: Aberrant glycosylation as possible target for personalized-medicine",

abstract = "One of the frontiers in cancer personalized-medicine aims at glycosylation. Cells are covered with a dense sugar coat of glycolipids, glycoproteins and free glycans. In cancer, the characteristic cell surface glycosylation is frequently transformed due to altered expression of glycan-modifying enzymes. This often leads to aberrant expression of sialic acids (Sia) that cap glycan-chains. Additionally, dietary intake of the non-human Sia N-glycolylneuraminic acid (Neu5Gc) leads to natural metabolic-glycoengineering of human carcinomas that accumulate and express Neu5Gc. This Sia provokes a polyclonal anti-Neu5Gc xeno-autoantibodies response that can exacerbate cancer. This review highlights cancer-associated changes in Sia expression and their potential for personalized-theranostics.",

keywords = "Antibodies, Cancer, Neu5Gc, Personalized-medicine, Sialic acids",

author = "Vered Padler-Karavani",

note = "Funding Information: I would like to thank Prof. Ajit Varki at The University of California San Diego for introducing me to the Sialic acid research and for his excellent mentorship over the years. This work was supported in part by grants from the Israeli National Nanotechnology Initiative and Helmsley Charitable Trust for a focal technology area on Nanomedicines for Personalized Theranostics and by the European Commission FP7 Marie-Curie grant (PIIF-GA-2012-327726) to V.P-K.",

year = "2014",

month = sep,

day = "28",

doi = "10.1016/j.canlet.2013.10.005",

language = "الإنجليزيّة",

volume = "352",

pages = "102--112",

journal = "Cancer Letters",

issn = "0304-3835",

publisher = "Elsevier Ireland Ltd",

number = "1",

}

TY - JOUR

T1 - Aiming at the sweet side of cancer

T2 - Aberrant glycosylation as possible target for personalized-medicine

AU - Padler-Karavani, Vered

N1 - Funding Information: I would like to thank Prof. Ajit Varki at The University of California San Diego for introducing me to the Sialic acid research and for his excellent mentorship over the years. This work was supported in part by grants from the Israeli National Nanotechnology Initiative and Helmsley Charitable Trust for a focal technology area on Nanomedicines for Personalized Theranostics and by the European Commission FP7 Marie-Curie grant (PIIF-GA-2012-327726) to V.P-K.

PY - 2014/9/28

Y1 - 2014/9/28

N2 - One of the frontiers in cancer personalized-medicine aims at glycosylation. Cells are covered with a dense sugar coat of glycolipids, glycoproteins and free glycans. In cancer, the characteristic cell surface glycosylation is frequently transformed due to altered expression of glycan-modifying enzymes. This often leads to aberrant expression of sialic acids (Sia) that cap glycan-chains. Additionally, dietary intake of the non-human Sia N-glycolylneuraminic acid (Neu5Gc) leads to natural metabolic-glycoengineering of human carcinomas that accumulate and express Neu5Gc. This Sia provokes a polyclonal anti-Neu5Gc xeno-autoantibodies response that can exacerbate cancer. This review highlights cancer-associated changes in Sia expression and their potential for personalized-theranostics.

AB - One of the frontiers in cancer personalized-medicine aims at glycosylation. Cells are covered with a dense sugar coat of glycolipids, glycoproteins and free glycans. In cancer, the characteristic cell surface glycosylation is frequently transformed due to altered expression of glycan-modifying enzymes. This often leads to aberrant expression of sialic acids (Sia) that cap glycan-chains. Additionally, dietary intake of the non-human Sia N-glycolylneuraminic acid (Neu5Gc) leads to natural metabolic-glycoengineering of human carcinomas that accumulate and express Neu5Gc. This Sia provokes a polyclonal anti-Neu5Gc xeno-autoantibodies response that can exacerbate cancer. This review highlights cancer-associated changes in Sia expression and their potential for personalized-theranostics.

KW - Antibodies

KW - Cancer

KW - Neu5Gc

KW - Personalized-medicine

KW - Sialic acids

UR - http://www.scopus.com/inward/record.url?scp=84906045911&partnerID=8YFLogxK

U2 - 10.1016/j.canlet.2013.10.005

DO - 10.1016/j.canlet.2013.10.005

M3 - مقالة مرجعية

C2 - 24141190

SN - 0304-3835

VL - 352

SP - 102

EP - 112

JO - Cancer Letters

JF - Cancer Letters

IS - 1

ER -

Aiming at the sweet side of cancer: Aberrant glycosylation as possible target for personalized-medicine

Abstract

Keywords

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this